Loraz and Hepatitis fulminant - a phase IV clinical study of FDA data

Summary:

Hepatitis fulminant is reported as a side effect among people who take Loraz (lorazepam), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Cymbalta, and have Psoriasis.

The phase IV clinical study analyzes which people have Hepatitis fulminant when taking Loraz. It is created by eHealthMe based on reports of 161,700 people who have side effects when taking Loraz from the FDA, and is updated regularly.

What is Loraz?

Loraz has active ingredients of lorazepam. It is often used in stress and anxiety. eHealthMe is studying from 165,695 Loraz users. Check the latest studies of Loraz.

What is Hepatitis fulminant?

Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function) is found to be associated with 449 drugs and 677 conditions by eHealthMe. Check the latest studies of Hepatitis fulminant.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 01, 2026

161,700 people reported to have side effects when taking Loraz.
Among them, 29 people (0.02%) have Hepatitis fulminant.

Could Loraz cause Hepatitis fulminant?

Among these 29 people:

How long have people been on Loraz when they have Hepatitis fulminant? *

  • < 1 month: 33.33 %
  • 1 - 6 months: 66.67 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Hepatitis fulminant when taking Loraz? *

  • female: 35.71 %
  • male: 64.29 %

What is the age of people who have Hepatitis fulminant when taking Loraz? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 3.57 %
  • 20-29: 0.0 %
  • 30-39: 10.71 %
  • 40-49: 3.57 %
  • 50-59: 35.71 %
  • 60+: 46.43 %

What are other drugs people take besides Loraz? *

  1. Cymbalta: 9 people, 31.03%
  2. Furosemide: 7 people, 24.14%
  3. Paracetamol: 7 people, 24.14%
  4. Bydureon: 6 people, 20.69%
  5. Vioxx: 5 people, 17.24%
  6. Aldactone: 4 people, 13.79%
  7. Lasix: 4 people, 13.79%
  8. Amiodarone Hydrochloride: 4 people, 13.79%
  9. Abacavir Sulfate: 3 people, 10.34%
  10. Cordarone: 3 people, 10.34%

What are other side effects people have besides Hepatitis fulminant? *

  1. Coma Hepatic (accumulation in the bloodstream of toxic substances that are normally removed by the liver leads coma): 5 people, 17.24%
  2. Dyspnea (difficult or laboured breathing): 5 people, 17.24%
  3. Weight Increased: 4 people, 13.79%
  4. Hepatic Necrosis (large portions of liver die off due to severe liver disease): 4 people, 13.79%
  5. Hepatic Failure (liver failure): 4 people, 13.79%
  6. Hepatitis (inflammation of the liver): 4 people, 13.79%
  7. Chronic Renal Failure (kidney failure): 3 people, 10.34%
  8. Drowsiness: 3 people, 10.34%
  9. Blood Ph Decreased: 2 people, 6.90%
  10. Renal Impairment (severely reduced kidney function): 2 people, 6.90%

What are the existing conditions these people have? *

  1. Type 2 Diabetes: 6 people, 20.69%
  2. Psoriasis (immune-mediated disease that affects the skin): 6 people, 20.69%
  3. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 5 people, 17.24%
  4. Localised Osteoarthritis (infection of joint affects only single joint): 3 people, 10.34%
  5. Hiv Infection: 3 people, 10.34%
  6. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 2 people, 6.90%
  7. Psychotic Disorder: 2 people, 6.90%
  8. Nausea (feeling of having an urge to vomit): 2 people, 6.90%
  9. Fever: 2 people, 6.90%
  10. Suicide Attempt: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Loraz and have Hepatitis fulminant?

- Check whether Hepatitis fulminant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Loraz:

  • Loraz (165,695 reports)

Hepatitis fulminant treatments and more:

How severe was Hepatitis fulminant and when was it recovered:

Expand to all the drugs that have ingredients of lorazepam:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Loraz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis fulminant:

Browse all the conditions that are associated with Hepatitis fulminant:

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on lorazepam (the active ingredients of Loraz) and Loraz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: